[Caelyx once again recommended in recurrent ovarian carcinoma].
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D008081:Liposomes; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000451:nursing*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000451:nursing*; D017410:Practice Guidelines as Topic; D006113:United Kingdom
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin